These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

987 related articles for article (PubMed ID: 22770960)

  • 41. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
    Fujii R; Schlom J; Hodge JW
    J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma.
    McMichael EL; Benner B; Atwal LS; Courtney NB; Mo X; Davis ME; Campbell AR; Duggan MC; Williams K; Martin K; Levine K; Olaverria Salavaggione GN; Noel T; Ganju A; Uppati S; Paul B; Olencki T; Teknos TN; Savvides P; Tridandapani S; Byrd JC; Caligiuri MA; Liu SV; Carson WE
    Clin Cancer Res; 2019 Aug; 25(16):4955-4965. PubMed ID: 31142501
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.
    Roberti MP; Rocca YS; Amat M; Pampena MB; Loza J; Coló F; Fabiano V; Loza CM; Arriaga JM; Bianchini M; Barrio MM; Bravo AI; Domenichini E; Chacón R; Mordoh J; Levy EM
    Breast Cancer Res Treat; 2012 Dec; 136(3):659-71. PubMed ID: 23065032
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells.
    Roda JM; Parihar R; Magro C; Nuovo GJ; Tridandapani S; Carson WE
    Cancer Res; 2006 Jan; 66(1):517-26. PubMed ID: 16397268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
    Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy.
    Bedi A; Chang X; Noonan K; Pham V; Bedi R; Fertig EJ; Considine M; Califano JA; Borrello I; Chung CH; Sidransky D; Ravi R
    Mol Cancer Ther; 2012 Nov; 11(11):2429-39. PubMed ID: 22927667
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cilengitide and Cetuximab Reduce Cytokine Production and Colony Formation of Head and Neck Squamous Cell Carcinoma Cells
    Wichmann G; Cedra S; Schlegel D; Kolb M; Wiegand S; Boehm A; Hofer M; Dietz A
    Anticancer Res; 2017 Feb; 37(2):521-527. PubMed ID: 28179297
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.
    Jaime-Ramirez AC; Mundy-Bosse BL; Kondadasula S; Jones NB; Roda JM; Mani A; Parihar R; Karpa V; Papenfuss TL; LaPerle KM; Biller E; Lehman A; Chaudhury AR; Jarjoura D; Burry RW; Carson WE
    J Immunol; 2011 Mar; 186(6):3401-9. PubMed ID: 21321106
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines.
    Lee J; Keam B; Park HR; Park JE; Kim S; Kim M; Kim TM; Kim DW; Heo DS
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5705-5715. PubMed ID: 36547689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.
    Parihar R; Dierksheide J; Hu Y; Carson WE
    J Clin Invest; 2002 Oct; 110(7):983-92. PubMed ID: 12370276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy.
    Lattanzio L; Denaro N; Vivenza D; Varamo C; Strola G; Fortunato M; Chamorey E; Comino A; Monteverde M; Lo Nigro C; Milano G; Merlano M
    Cancer Immunol Immunother; 2017 May; 66(5):573-579. PubMed ID: 28197666
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma.
    Watanabe M; Kono K; Kawaguchi Y; Mizukami Y; Mimura K; Maruyama T; Fujii H
    Br J Cancer; 2010 Feb; 102(3):520-9. PubMed ID: 20029417
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
    Kondo N; Tsukuda M; Taguchi T; Nakazaki K; Sakakibara A; Takahashi H; Toth G; Nishimura G
    Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
    Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
    Front Immunol; 2018; 9():2140. PubMed ID: 30294328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
    Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
    Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids.
    Klöss S; Chambron N; Gardlowski T; Weil S; Koch J; Esser R; Pogge von Strandmann E; Morgan MA; Arseniev L; Seitz O; Köhl U
    Front Immunol; 2015; 6():543. PubMed ID: 26579120
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor-Specific Antibody, Cetuximab, Enhances the
    Jin WJ; Erbe AK; Schwarz CN; Jaquish AA; Anderson BR; Sriramaneni RN; Jagodinsky JC; Bates AM; Clark PA; Le T; Lan KH; Chen Y; Kim K; Morris ZS
    Front Immunol; 2020; 11():591139. PubMed ID: 33281820
    [TBL] [Abstract][Full Text] [Related]  

  • 58. EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.
    Fletcher EV; Love-Homan L; Sobhakumari A; Feddersen CR; Koch AT; Goel A; Simons AL
    Mol Cancer Res; 2013 Dec; 11(12):1574-84. PubMed ID: 24048704
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells.
    Fantini M; David JM; Wong HC; Annunziata CM; Arlen PM; Tsang KY
    Cancer Biother Radiopharm; 2019 Apr; 34(3):147-159. PubMed ID: 30601063
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity.
    Hara M; Nakanishi H; Tsujimura K; Matsui M; Yatabe Y; Manabe T; Tatematsu M
    Cancer Sci; 2008 Jul; 99(7):1471-8. PubMed ID: 18422755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.